COMPANY:

Helio Genomics

"Helio Genomics...presented and discussed recent CLiMB trial data evaluating HelioLiver, a multi-analyte blood test, in patients with hepatocellular carcinoma (HCC), as well as its cell-free DNA (cfDNA) methylation biomarkers for assessing prognosis and treatment response at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting held November 18, 2024 and virtual KOL event held November 25, 2024. Both events featured Helio’s Chief Medical Advisor, Dr. Richard Van Etten, MD, PhD."

"Helio Genomics...announced that results from an important new research study have been published in the peer-reviewed journal, Genome Medicine...The study is entitled 'Multimodal Epigenetic Sequencing Analysis (MESA) of Cell-free DNA for Non-invasive Colorectal Cancer Detection'. This study was conducted as a collaboration between Helio Genomics, its sister company and the Division of Computational Biomedicine at the University of California, Irvine."

"Helio Genomics said Thursday that its sister company, Laboratory for Advanced Medicine & Health Group (LAMH), has received approval from the National Medical Products Administration (NMPA) in China for its cell-free DNA-based liver cancer detection test. The assay is the first of its kind to receive this approval...The test is an adaptation of Helio's HelioLiver test that is specifically tailored for the genetic makeup of the Asia-Pacific population. The company estimated that 87 million people in China live with hepatitis B, a risk factor for liver cancer, representing one third of the hepatitis B population in the world."

"Helio Genomics ("Helio"), and its commercial partner, Fulgent Genetics (NASDAQ: FLGT) ("Fulgent") announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022."

"Helio Health ("Helio")...today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver's strong clinical performance in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most common cancer worldwide but the second in cancer-related mortality, often due to late diagnosis."

"Helio Health...and its commercial partner, Fulgent Genetics, Inc...today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an area where traditional standard-of-care imaging tools often fall short, with the potential to enable more curative treatment options known to increase five-year survival rates by up to 13 times compared to when cancer has metastasized."

"Helio Health...and Fulgent Genetics, Inc...announced its upcoming late-breaking poster presentation on the performance of HelioLiver, a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers for the detection of hepatocellular carcinoma (HCC), at The Liver Meeting® 2021. The annual meeting is hosted by the American Association for the Study of Liver Diseases (AASLD) and will be held virtually November 12-15, 2021."